March 13th 2025
Sarita Shah, MD, MPH, reveals a decline in timely ART initiation from 86.5% in 2019 to 83.9% in 2020, with viral suppression rates dropping from 91.1% to 84.7%, before showing signs of recovery by 2021.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
AstraZeneca COVID-19 Vaccine Linked to Rare Thrombosis, Thrombocytopenia Events
April 9th 2021The newest research of rare adverse events among patients administered the vaccine highlights that venous or arterial thrombosis can develop in unexpected regions, including the brain or abdomen, 5-20 days after administration.
Read More
Canada Recommends Not Using AstraZeneca COVID-19 Vaccines in People 55 and Younger
March 30th 2021The country’s federal health agency decided upon this action based on the small number of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) incidents in Europe, which are being investigated.
Read More
Escalated Anticoagulation Shows No Benefit Over Standard Dosing for COVID-19 Patients in ICU
March 29th 2021Intermediate-dose prophylactic anticoagulation did not improve mortality or venous or arterial thrombosis in patients with COVID-19 in the ICU compared with standard dosing, a new study found.
Read More
NIAID, Review Board Challenges New AstraZeneca COVID-19 Vaccine Data
March 23rd 2021A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”
Read More